Harrow (HROW), an eyecare pharmaceutical company, continues to attract attention as investors weigh its recent share performance, business mix across branded and compounding segments, and the implications for the stock’s current US$40.44 trading level.

The recent 1-day share price return of 1.30% and 7-day share price return of 4.31% come after a 30-day share price decline of 10.27%. At the current US$40.44 level, a 1-year total shareholder return of 17.46% and a very large 5-year total shareholder return indicate that Harrow’s longer term momentum has been stronger than its shorter term pullback.

If you are comparing Harrow with other opportunities in healthcare and eyecare, this could be a useful moment to scan for 43 healthcare AI stocks

After Harrow’s pullback, yet with a wide gap to analyst targets and intrinsic estimates, the real question is where fair value sits within that spread. Is the recent share price move tightening that gap or leaving upside on the table?

Most Popular Narrative: 40.9% Undervalued

The most followed Harrow narrative places fair value at $68.38, well above the recent $40.44 close. This creates a wide valuation gap for investors to assess.

Operating leverage is set to improve meaningfully as Harrow's scalable commercial infrastructure, already built out and profitable, absorbs additional high-margin revenue from both organic growth (e.g., expanded refill rates, market share gains) and new product launches, likely driving further net margin expansion.

Want to see what underpins that fair value call for Harrow? The narrative focuses on rapid revenue expansion, sharply higher margins and a future earnings profile reshaped by its ophthalmic portfolio.

Result: Fair Value of $68.38 (UNDERVALUED)

However, Harrow’s reliance on a handful of flagship products, along with uncertainty around future drug pricing, could still upset this undervaluation narrative.

Another View on Harrow’s Valuation

The first narrative leans heavily on future earnings to argue Harrow is 40.9% undervalued with a fair value of $68.38. On simple P/S, though, Harrow trades at 5.6x, slightly above both the US Pharmaceuticals average of 5.2x and peer average of 5.3x, while the fair ratio model points to 8.2x. That mix of a slight premium today and a higher fair ratio target raises a practical question for you: Is this a valuation risk to be cautious about, or a pricing gap you are willing to underwrite?

Next Steps

If the mixed signals around Harrow have you curious, take a closer look at the underlying numbers yourself and decide quickly where you stand on the stock. You can start by checking the 2 key rewards

Looking for more investment ideas beyond Harrow?

Do not stop with Harrow. Broaden your watchlist with a few focused stock ideas picked from different angles that could help inform your next move.

• Scan for potential mispriced quality by reviewing the 51 high quality undervalued stocks that combine solid fundamentals with appealing valuations.
• Strengthen your income stream by checking the 8 dividend fortresses that offer higher yields supported by resilient payout histories.
• Prioritise stability in your portfolio by focusing on the 79 resilient stocks with low risk scores that score well on financial health and volatility.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.